Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
Sign Up to like & getrecommendations! Published in 2022 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-022-01681-y
Abstract: Definite cure remains exceptional in myeloma patients even after high-dose chemotherapy (HDCT) with melphalan (Mel) and autologous stem cell transplantation (ASCT). Thus, improving efficacy of HDCT in MM remains an unresolved issue. This randomized phase… read more here.
Keywords: myeloma; melphalan; phase trial; hdct ... See more keywords
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.01325
Abstract: High-dose chemotherapy (HDCT) has curative potential in relapsed/refractory germ cell tumors (GCT). Due to the complexity of this population and the toxicity of HDCT, we evaluated the association between blood-based systemic inflammatory indexes and the… read more here.
Keywords: dose chemotherapy; high dose; inflammatory; germ cell ... See more keywords